A Curative Effect Evaluation of Intensity-modulated Radiation Therapy Combined with Periorbital Triamcinolone Acetonide Injection in Treating Thyroid Eye Disease Patients with Active Extraocular Muscle but Low CAS

Overview

Journal Sci Rep

Date 2025 Jan 25

PMID 39863792

Authors

Hao Zhang

Weimin He

Affiliations

Soon will be listed here.

Abstract

The purpose of this study is to evaluate the effectiveness of intensity-modulated radiation therapy (IMRT) combined with periorbital triamcinolone acetonide injection in treating thyroid eye disease (TED) patients with active extraocular muscle but low CAS. The retrospective observational study was conducted. A total of 156 eligible patients were selected from the TED patient database of the Ophthalmology Department of West China Hospital of Sichuan University. The patient's relevant medical history was recorded, including gender, age of initial onset, onset eye, the interval between onset and the first visit to our hospital, extraocular muscle condition, smoking status, CAS, NOSPECS, thyroid function, symptoms and signs, and the condition of the affected extraocular muscle. We found that IMRT combined with periorbital triamcinolone acetonide injection has a good therapeutic effect on TED patients with low CAS but significant active extraocular muscles, and there is a significant improvement at 3 months after treatment. Thyroid function and CAS can affect the curative effect of IMRT. Patients with hyperthyroidism had worse effect than those with normal thyroid function. The higher the CAS, the better the effect.

References

Bartley G, Gorman C . Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 1995; 119(6):792-5. DOI: 10.1016/s0002-9394(14)72787-4. View

Marino M, Ionni I, Lanzolla G, Sframeli A, Latrofa F, Rocchi R . Orbital diseases mimicking graves' orbitopathy: a long-standing challenge in differential diagnosis. J Endocrinol Invest. 2019; 43(4):401-411. DOI: 10.1007/s40618-019-01141-3. View

Hiromatsu Y, Eguchi H, Tani J . [Management of Graves' ophthalmopathy by using orbital magnetic resonance imaging]. Nihon Rinsho. 2012; 70(11):1932-7. View

Li Y, Luo Y, He W, Li P, Wang F . Clinical outcomes of graves' ophthalmopathy treated with intensity modulated radiation therapy. Radiat Oncol. 2017; 12(1):171. PMC: 5674803. DOI: 10.1186/s13014-017-0908-7. View

Bartalena L, Kahaly G, Baldeschi L, Dayan C, Eckstein A, Marcocci C . The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021; 185(4):G43-G67. DOI: 10.1530/EJE-21-0479. View

Siakallis L, Uddin J, Miszkiel K . Imaging Investigation of Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018; 34(4S Suppl 1):S41-S51. DOI: 10.1097/IOP.0000000000001139. View

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly G, Marcocci C . The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016; 5(1):9-26. PMC: 4836120. DOI: 10.1159/000443828. View

Mourits M, Koornneef L, Wiersinga W, Prummel M, Berghout A, van der Gaag R . Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989; 73(8):639-44. PMC: 1041835. DOI: 10.1136/bjo.73.8.639. View

Li Y, Luo Y, Xie X, He W, Yi C, Li P . The efficacy of intensity modulated radiation therapy in treating thyroid-associated ophthalmopathy and predictive factors for treatment response. Sci Rep. 2017; 7(1):17533. PMC: 5727475. DOI: 10.1038/s41598-017-17893-y. View

10.

Prabhu R, Liebman L, Wojno T, Hayek B, Hall W, Crocker I . Clinical outcomes of radiotherapy as initial local therapy for Graves' ophthalmopathy and predictors of the need for post-radiotherapy decompressive surgery. Radiat Oncol. 2012; 7:95. PMC: 3485155. DOI: 10.1186/1748-717X-7-95. View

11.

Tian S, Nishida Y, Isberg B, Lennerstrand G . MRI measurements of normal extraocular muscles and other orbital structures. Graefes Arch Clin Exp Ophthalmol. 2000; 238(5):393-404. DOI: 10.1007/s004170050370. View

12.

Barrio-Barrio J, Sabater A, Bonet-Farriol E, Velazquez-Villoria A, Galofre J . Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol. 2015; 2015:249125. PMC: 4553342. DOI: 10.1155/2015/249125. View

13.

Bahn R . Graves' ophthalmopathy. N Engl J Med. 2010; 362(8):726-38. PMC: 3902010. DOI: 10.1056/NEJMra0905750. View

14.

Han Q, Mao X, Tian S . A retrospective study on the effectiveness of intensity modulated radiation therapy for thyroid associated ophthalmopathy at a single institute. Sci Rep. 2024; 14(1):17834. PMC: 11294557. DOI: 10.1038/s41598-024-68809-6. View

15.

Hiromatsu Y, Eguchi H, Tani J, Kasaoka M, Teshima Y . Graves' ophthalmopathy: epidemiology and natural history. Intern Med. 2014; 53(5):353-60. DOI: 10.2169/internalmedicine.53.1518. View

16.

Zeng L, Xie X, Li C, Shi H, Wang F . Clinical study of the radiotherapy with EDGE accelerator in the treatment of the moderate and severe thyroid associated ophthalmopathy. Eur Rev Med Pharmacol Sci. 2019; 23(8):3471-3477. DOI: 10.26355/eurrev_201904_17712. View

17.

Tortora F, Cirillo M, Ferrara M, Belfiore M, Carella C, Caranci F . Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score. Neuroradiol J. 2013; 26(5):555-64. PMC: 4202826. DOI: 10.1177/197140091302600509. View